Boehringer Ingelheim and HealthPrize Technologies are expanding the RespiPoints digital support program to anyone taking one of several Boehringer Ingelheim medicines, including select medicines available in the Respimat inhaler.
The RespiPoints program is a free web and mobile-based program that engages and rewards patients through education about their condition and support to take their medicines daily as prescribed by their healthcare provider.
Launched through an initial nine-month pilot in 2016, the RespiPoints program showed participants increased their knowledge of COPD and began following healthy habits. For example, participants showed an improved adherence in their medicines, resulting in an 85% decrease in gap days between refilling their next prescription. As with other chronic conditions, poor adherence to medicines is common among patients with respiratory conditions, and can result in increased rates of symptoms, healthcare costs and hospitalizations.
Patients enrolled in the RespiPoints program participate in a variety of activities to earn points, which can be redeemed for e-gift cards. Activities include reporting daily medicine taking, verifying monthly refills, reading educational information and insightful tips and completing weekly quizzes and surveys.
“We strongly support the role of innovative health technology solutions in respiratory treatment plans to help improve healthcare outcomes,” said Jean-Michel Boers, president Human Pharma Boehringer Ingelheim Pharmaceuticals Inc. “We partnered with HealthPrize to adapt their interactive patient solution, and we are very pleased with the impact of RespiPoints, which has made a positive difference in patients’ adherence to daily treatment plans and their understanding of the disease.”